Quick Answer
Vanda Pharmaceuticals Inc. reported Stockholders Equity of $327.19 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $327.19M | -39.2% |
| 2024 | $538.55M | -1.2% |
| 2023 | $544.91M | +3.4% |
| 2022 | $527.20M | +4.4% |
| 2021 | $504.93M | +11.4% |
| 2020 | $453.27M | +10.3% |
| 2019 | $410.94M | +49.2% |
| 2018 | $275.42M | +109.6% |
| 2017 | $131.39M | +0.0% |
| 2016 | $131.33M | -1.3% |
| 2015 | $133.03M | -17.3% |
| 2014 | $160.82M | +264.5% |
| 2013 | $44.12M | +345.5% |
| 2012 | $9.90M | -70.4% |
| 2011 | $33.47M | -11.3% |
| 2010 | $37.73M | +63.8% |
| 2009 | $23.03M | -50.0% |
| 2008 | $46.02M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $466.00M | -13.9% | -4.2% |
| June 30, 2025 | $486.33M | -10.4% | -4.9% |
| March 31, 2025 | $511.42M | -6.0% | -5.0% |
| December 31, 2024 | $538.55M | -1.2% | -0.5% |
| September 30, 2024 | $541.22M | -0.3% | -0.2% |
| June 30, 2024 | $542.52M | +0.5% | -0.3% |
| March 31, 2024 | $544.00M | +1.5% | -0.2% |
| December 31, 2023 | $544.91M | +3.4% | +0.3% |
- Vanda Pharmaceuticals Inc. showed a decrease of -39.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, Vanda Pharmaceuticals Inc.’s stockholders equity has grown by 611.0% (from $46.02 million to $327.19 million).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: